Madhunapantula SV - Search Results

1

Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.

Sharma A, Madhunapantula SV, Robertson GP. Sharma A, et al. Among authors: madhunapantula sv. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47-69. doi: 10.1517/17425255.2012.637916. Epub 2011 Nov 19. Expert Opin Drug Metab Toxicol. 2012. PMID: 22097965 Free PMC article. Review.

2

Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Gowda R, et al. Among authors: madhunapantula sv. Mol Cancer Ther. 2014 Oct;13(10):2328-40. doi: 10.1158/1535-7163.MCT-14-0357. Epub 2014 Jul 31. Mol Cancer Ther. 2014. PMID: 25082958 Free PMC article.

3

PRAS40 deregulates apoptosis in malignant melanoma.

Madhunapantula SV, Sharma A, Robertson GP. Madhunapantula SV, et al. Cancer Res. 2007 Apr 15;67(8):3626-36. doi: 10.1158/0008-5472.CAN-06-4234. Cancer Res. 2007. PMID: 17440074

4

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Madhunapantula SV, Robertson GP. Madhunapantula SV, et al. Cancer Res. 2008 Jan 1;68(1):5-8. doi: 10.1158/0008-5472.CAN-07-2038. Cancer Res. 2008. PMID: 18172288 Review.

5

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Cheung M, et al. Among authors: madhunapantula sv. Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867. Cancer Res. 2008. PMID: 18451171 Free PMC article.

6

PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.

Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. Madhunapantula SV, et al. Mol Cancer Ther. 2008 May;7(5):1297-308. doi: 10.1158/1535-7163.MCT-07-2267. Mol Cancer Ther. 2008. PMID: 18483317

7

Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.

Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S. Sharma AK, et al. Among authors: madhunapantula sv. J Med Chem. 2008 Dec 25;51(24):7820-6. doi: 10.1021/jm800993r. J Med Chem. 2008. PMID: 19053750 Free PMC article.

8

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP. Sharma A, et al. Among authors: madhunapantula sv. Clin Cancer Res. 2009 Mar 1;15(5):1674-85. doi: 10.1158/1078-0432.CCR-08-2214. Epub 2009 Feb 10. Clin Cancer Res. 2009. PMID: 19208796 Free PMC article.

9

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Madhunapantula SV, Robertson GP. Madhunapantula SV, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):400-19. doi: 10.1111/j.1755-148X.2009.00585.x. Epub 2009 May 28. Pigment Cell Melanoma Res. 2009. PMID: 19493313 Free PMC article. Review.

10

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Inamdar GS, Madhunapantula SV, Robertson GP. Inamdar GS, et al. Among authors: madhunapantula sv. Biochem Pharmacol. 2010 Sep 1;80(5):624-37. doi: 10.1016/j.bcp.2010.04.029. Epub 2010 May 9. Biochem Pharmacol. 2010. PMID: 20450891 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters